Image Place holder

Alison Walker, MD, MPH, MBA

 
Specialty: Hematology/Oncology
Program: Malignant Hematology

Overview

Cancer Focus: Leukemia, Myelodysplastic Syndromes (MDS)

Dr. Walker received her MD from University of Rochester School of Medicine and Dentistry. She completed an Internal Medicine Residency and a Hematology/Oncology Fellowship at the University of Rochester, New York. She joins us from The Ohio State University, where she served as a Professor in the Department of Internal Medicine, Division of Hematology. Dr. Walker’s clinical interests are in the care of patients with myeloid malignancies, specifically acute myeloid leukemia and myelodysplastic syndromes. She is particularly interested in identifying ways to deliver care that maximizes resource utilization and achieves superior patient satisfaction. Dr. Walker’s research interests are in the development of experimental therapeutics and phase I clinical trials for patients with acute myeloid leukemia and myelodysplastic syndromes, focusing on novel therapeutics that target aberrant mechanisms of leukemogenesis.


Education & Training

Residency:

  • Strong Memorial Hospital -

Medical School:

  • University of Rochester School of Medicine and Dentistry - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu E, Frissora F, Mo X, Walker LA, Yan P, Bundschuh R, Beaver L, Devine R, Tsai YT, Ventura A, Xie Z, Chen M, Lapalombella R, Walker A, Mims A, Larkin K, Grieselhuber N, Bennett C, Phelps M, Hertlein E, Behbehani G, Vasu S, Byrd JC, Muthusamy N. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood. 2022 Mar.139(9):1340-1358. Pubmedid: 34788382. Pmcid: PMC8900275.
  • Ritchie EK, Klepin HD, Storrick E, Major-Elechi BT, Le-Rademacher J, Wadleigh M, Walker AR, Larson RA, Roboz GJ. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022 Jun.6(12):3812-3820. Pubmedid: 35420672.
  • Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR. Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients. Hematol Oncol. 2022 Feb.40(1):115-118. Pubmedid: 34713477.
  • Liva S, Chen M, Mortazavi A, Walker A, Wang J, Dittmar K, Hofmeister C, Coss CC, Phelps MA. Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. Eur J Drug Metab Pharmacokinet. 2021 Nov.46(6):807-816. Pubmedid: 34618345. Pmcid: PMC8599380.
  • Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C. Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms. Am J Hematol. 2021 Jul.96(7):E223-E225. Pubmedid: 33761147.
  • King AA, Vesely SK, Dadzie G, Calhoun C, Cuker A, Stock W, Walker A, Fritz J, Sung L. Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. Blood Adv. 2021 Jul.5(14):2919-2924. Pubmedid: 34309634. Pmcid: PMC8341353.
  • Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrózek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 Jul.5(13):2775-2787. Pubmedid: 34251414. Pmcid: PMC8288671.
  • Ozga M, Huang Y, Blachly JS, Grieselhuber NR, Wall S, Larkin K, Haque T, Walker AR, Bhatnagar B, Behbehani G, Vasu S, Maakaron JE, Lustberg M, Mims AS. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e76-e83. Pubmedid: 32921593.
  • El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, Hobbs GS, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA, Temel JS. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2021 Feb.7(2):238-245. Pubmedid: 33331857. Pmcid: PMC7747042.
  • Ali AM, Cooper J, Walker A, Jones D, Saad A. Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL. Brit J Haematol. 2021 Feb.192(3):665-667. Pubmedid: 33216958.
  • Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS. Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia. 2021 Dec.35(12):3406-3420. Pubmedid: 34021247. Pmcid: PMC8606012.
  • Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS. Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia. 2021 Dec.35(12):3627. Pubmedid: 34480107. Pmcid: PMC8632666.
  • Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. Int J Hematol Oncol. 2020 Sep.9(3):IJH28. Pubmedid: 33014332. Pmcid: PMC7521187.
  • Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 Oct.4(19):4945-4954. Pubmedid: 33049054. Pmcid: PMC7556122.
  • Walker AR, Byrd JC, Blachly JS, Bhatnagar B, Mims AS, Orwick S, Lin TL, Crosswell HE, Zhang D, Minden MD, Munugalavadla V, Long L, Liu J, Pan Y, Oellerich T, Serve H, Rao AV, Blum WG. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clin Cancer Res. 2020 Nov.26(22):5852-5859. Pubmedid: 32820015.
  • Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker AR. Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leuk Lymphoma. 2020 Jun.61(6):1484-1492. Pubmedid: 32037935. Pmcid: PMC7375689.
  • Patel SH, Vasu S, Guo L, Lemaster O, Byrd JC, Walker A. Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia. J Natl Compr Canc Ne. 2020 Jan.18(1):6-10. Pubmedid: 31910380. Pmcid: PMC8162795.
  • Saygin C, Grieselhuber N, Blachly J, Byrd JC, Vasu S, Larkin K, Behbehani G, Long M, Walker A, Bhatnagar B, Mims A. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia. Leuk Res. 2020 Feb.89:106297. Pubmedid: 31935625.
  • Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, Pikman Y, Robichaud A, Goodale A, Häupl B, Mohr S, Rao AV, Walker AR, Blachly JS, Piccioni F, Armstrong SA, Byrd JC, Oellerich T, Stegmaier K. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2020 Feb.10(2):214-231. Pubmedid: 31771968. Pmcid: PMC7058374.
  • Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma. 2020 Feb.61(2):387-396. Pubmedid: 31545113. Pmcid: PMC7552944.
  • Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 Dec.26(12):1852-1858. Pubmedid: 33106665. Pmcid: PMC8530434.
  • Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 Dec.95(12):1457-1465. Pubmedid: 32777116. Pmcid: PMC7821016.
  • Walker AR. How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2020 Dec.2020(1):51-56. Pubmedid: 33275685. Pmcid: PMC7727520.
  • Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drugs. 2020 Apr.38(2):340-349. Pubmedid: 31102119. Pmcid: PMC6858927.
  • DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, Röllig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 Oct.85:106197. Pubmedid: 31541945. Pmcid: PMC7108400.
  • Levine LB, Roddy JV, Kim M, Li J, Phillips G, Walker AR. A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. J Oncol Pharm Pract. 2018 Jun.24(4):290-298. Pubmedid: 28345491. Pmcid: PMC7154947.
  • Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica. 2018 Jun.103(6):982-987. Pubmedid: 29567781. Pmcid: PMC6058798.
  • Vaughn JL, Kline D, Denlinger NM, Andritsos LA, Exline MC, Walker AR. Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy. Leuk Lymphoma. 2018 Jun.59(6):1498-1500. Pubmedid: 28901797. Pmcid: PMC7132216.
  • Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 2018 Feb.9(11):9706-9713. Pubmedid: 29515764. Pmcid: PMC5839395.
  • Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 Dec.2(24):3608-3617. Pubmedid: 30567725. Pmcid: PMC6306886.
  • Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica. 2018 Aug.103(8):1288-1297. Pubmedid: 29773600. Pmcid: PMC6068035.
  • Yao C, Zhang G, Walker A, Zhao KY, Li Y, Lyu L, Tang Y, Ru P, Jones D, Zhao W. Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines. Leuk Res. 2017 Sep.60:129-134. Pubmedid: 28818808.
  • Bond DA, Huang Y, Ruppert AS, Walker AR, Dotson EK, Roddy J, Blum KA, Christian BA. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. Leuk Lymphoma. 2017 Jul.58(7):1589-1597. Pubmedid: 27838951. Pmcid: PMC5499523.
  • Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Jan.15(1):60-87. Pubmedid: 28040720.
  • Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2016 Sep.57(9):2100-2108. Pubmedid: 26784138. Pmcid: PMC5360182.
  • Walker AR. Dying a fiery death: pyroptosis in MDS. Blood. 2016 Oct.128(25):2875-2877. Pubmedid: 28007731.
  • Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci G. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia. 2016 Apr.30(4):789-799. Pubmedid: 26536822. Pmcid: PMC8034866.
  • Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood. 2015 Apr.125(17):2689-2692. Pubmedid: 25716206. Pmcid: PMC4408293.
  • Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum W. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2014 Jun.55(6):1304-1308. Pubmedid: 23952243. Pmcid: PMC3925754.
  • Walker AR, Marcucci G. Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers. J Natl Compr Canc Ne. 2014 Apr.12(4):527-534. Pubmedid: 24717571.
  • Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2013 Sep.54(9):1996-2002. Pubmedid: 23256542. Pmcid: PMC3860322.
  • Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct.72(4):897-908. Pubmedid: 23949430. Pmcid: PMC3784060.
  • Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013 May.19(9):2355-2367. Pubmedid: 23493348. Pmcid: PMC3644023.
  • Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 2013 Jan.121(1):159-169. Pubmedid: 23100311. Pmcid: PMC3538328.
  • Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. AAPS J. 2013 Jan.15(1):242-249. Pubmedid: 23180159. Pmcid: PMC3535094.
  • Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec.37(12):1622-1627. Pubmedid: 24138944.
  • Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013 Apr.27(4):871-878. Pubmedid: 23178755. Pmcid: PMC3764604.
  • Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. Gene Chromosome Canc. 2013 Apr.52(4):385-401. Pubmedid: 23225546. Pmcid: PMC3874732.
  • Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci G. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012 Sep.120(12):2466-2474. Pubmedid: 22786882. Pmcid: PMC3448258.
  • Walker A, Marcucci G. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol. 2012 Oct.5(5):547-558. Pubmedid: 23146058. Pmcid: PMC3582378.
  • Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012 May.26(5):1106-1107. Pubmedid: 22124213. Pmcid: PMC3696987.
  • Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci G. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012 Jun.119(25):6025-6031. Pubmedid: 22566605. Pmcid: PMC3383015.
  • Racke F, Cole C, Walker A, Jones J, Heerema NA. Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification. Cancer Genet. 2012 Dec.205(12):653-656. Pubmedid: 23238285. Pmcid: PMC4032176.
  • Baikaidi M, Chung SS, Tallman MS, Damon LE, Walker AR, Marcucci G, Sholi AM, Morris GJ. A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma). Semin Oncol. 2012 Dec.39(6):e37-e46. Pubmedid: 23206848. Pmcid: PMC3969822.
  • Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012 Aug.120(9):1765-1773. Pubmedid: 22677130. Pmcid: PMC3433086.
  • Walker A, Marcucci G. Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse. Haematologica. 2011 May.96(5):640-643. Pubmedid: 21531946. Pmcid: PMC3084908.
  • Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010 Nov.28(33):4919-4925. Pubmedid: 20956622. Pmcid: PMC3020696.
  • Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010 Apr.107(16):7473-7478. Pubmedid: 20368434. Pmcid: PMC2867720.
  • Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest. 2008 May.26(4):431-433. Pubmedid: 18443965.
  • Walker AR, Komrokji RJ, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec.32(12):1830-1836. Pubmedid: 18571721.
  • Walker AR, Rothberg PG, Liesveld JL. A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML. Bone Marrow Transplant. 2007 Jun.39(11):725-726. Pubmedid: 17401398.

Patient Comments
Overall Satisfaction
5

7 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments